2 results
Approved WMOPending
The primary objective is to investigate the effect of bepranemab (45mg/kg and 90mg/kg Q4W) vs placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), a scale used to quantify the severity of symptoms of dementia, as the change from…
Approved WMOCompleted
The primary objective of this trial is to investigate the proposed beneficial effect of raloxifene as compared to placebo when given for twelve weeks in addition to antipsychotic medication to patients with a psychotic disorder. We expect lower…